 NEW YORK, April 1, 2021 PRNewswire -- Relmada Therapeutics, Inc. Nasdaq: RLMD, a late-stage biotechnology company addressing diseases of the central nervous system CNS, today announced the initiation of the second of the two sister pivotal Phase 3 clinical trials RELIANCE I and RELIANCE II for the Companys lead product candidate, REL-1017, as an adjunctive treatment for major depressive disorder MDD. We are pleased to begin enrolling patients into the second Phase 3 clinical trial of REL-1017 in MDD, a condition impacting more than 17 million individuals in the U.S., with limited safe and effective therapeutic options currently available, said Sergio Traversa, Relmadas Chief Executive Officer. 